Status
Conditions
Treatments
About
Ablation of atrial fibrillation is standard therapy for symptomatic patients or patients with severely reduced systolic left ventricular ejection fraction. Complications of the procedure are ischemic thrombembolic stroke. Therefore periprocedural treatment with heparin is administered to acchieve a therapeutic anticoagulation. The efficacy of anticoagulation is measured by active-clotting time (ACT) which is measured with blood drawn mostly from the V. femoralis.
Despite controlled anticoagulation periprocedural stroke is published with an incidence of up to 2% and asymptomatic cerebral embolization from 2% to 15%.
The ACT-Trial has two aims:
Patients will be included scheduled for left atrial ablation procedure and will be divided in two groups: atrial fibrillation at time of procedure and sinus rhythm at time of procedure.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Incompliance or contraindication of oral anticoagulation prior to ablation procedure.
Loading...
Central trial contact
Clemens Jilek, PD Dr; Anna Hollweg
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal